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Morphogenesis of the cardiac arterial pole is dependent on addition of myocardium and smooth muscle from the secondary heart field and
septation by cardiac neural crest cells. Cardiac neural crest ablation results in persistent truncus arteriosus and failure of addition of myocardium
from the secondary heart field leading to malalignment of the arterial pole with the ventricles. Previously, we have shown that elevated FGF
signaling after neural crest ablation causes depressed Ca2+ transients in the primary heart tube. We hypothesized that neural crest ablation results in
elevated FGF8 signaling in the caudal pharynx that disrupts secondary heart field development. In this study, we show that FGF8 signaling is
elevated in the caudal pharynx after cardiac neural crest ablation. In addition, treatment of cardiac neural crest-ablated embryos with FGF8b
blocking antibody or an FGF receptor blocker rescues secondary heart field myocardial development in a time- and dose-dependent manner.
Interestingly, reduction of FGF8 signaling in normal embryos disrupts myocardial secondary heart field development, resulting in arterial pole
malalignment. These results indicate that the secondary heart field myocardium is particularly sensitive to FGF8 signaling for normal conotruncal
development, and further, that cardiac neural crest cells modulate FGF8 signaling in the caudal pharynx.
© 2006 Elsevier Inc. All rights reserved.Keywords: Heart development; FGF8, outflow tract; Arterial pole; Cardiac neural crest; Secondary heart field; Double outlet right ventricle; Persistent truncus
arteriosus; Calcium transient; mkp3Introduction
Development of the arterial pole of the 4-chambered heart
requires complex morphogenetic movements to establish a
single vascular channel with a myocardial-to-vascular smooth
muscle interface. This single vascular channel is later divided
into two outflow vessels by the cardiac neural crest cells (CNC).
Finally, the two outflow vessels are remodeled to align themwith
the right and left ventricles.
The secondary heart field (SHF) has recently been shown to
provide the myocardial–smooth muscle interface at the arterial
pole (Waldo et al., 2005a). The SHF-derived myocardium gives⁎ Corresponding author. Fax: +1 919 668 1599.
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myocardium is critical for normal alignment of the two outflow
vessels with respect to the ventricles (Yelbuz et al., 2002;Ward et
al., 2005). Clinically, malalignment of the arterial pole occurs in
the conotruncal defects, as seen in double outlet right ventricle
(DORV) and tetralogy of Fallot. In both of these defects, the
aorta overrides the ventricular septum. Recently, we have shown
that CNC are needed for normal development of the myocardial
component of the SHF prior to the time they begin septation of
the outflow vessels (Waldo et al., 2005b). Ablation of the pre-
migratory CNC results in both the absence of septation, as well
as, malalignment of the arterial pole because of the failure of the
SHF myocardium to develop normally. It is not known how
CNC affect SHF development because the two cell populations
are not in proximity when defective development of the SHF
occurs.
In chick embryos, the CNC begin their migration into the
caudal pharynx (arches 3–6) at stage 10 (Hamburger–Hamilton
stages). At stage 12, the CNC pause in the circumpharyngeal
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beginning at late stage 13, they populate the dorsal third pha-
ryngeal arch by migrating between the pharyngeal ectoderm and
endoderm. This is repeated as the succeeding arches 4 and 6
develop. It is during this period that the myocardium is added to
the outflow tract from the SHF. At stage 22, almost 4 days after
leaving the dorsal neural tube, CNC finally migrate into the
cardiac outflow tract where they will form the aorticopulmonary
septation complex that will divide the outflow into the aorta and
pulmonary trunk.
TheSHF is the splanchnicmesoderm located in the floor of the
caudal pharynx behind the outflow attachment to the pharynx.
Beginning at stage 14, the SHF migrates into the outflow
providing truncal myocardium and allowing lengthening of the
looping primary heart tube until stage 18 (Waldo et al., 2001,
2005a; Mjaatvedt et al., 2001; Kelly et al., 2001). Recently, we
have shown that the heart tube is shortened and abnormally
looped after neural crest ablation (NCA) because of the failure
of the SHF-derived myocardium to migrate into the outflow and
ultimately leads to malalignment of the outflow vessel (Yelbuz
et al., 2002; Waldo et al., 2005b). Because abnormal looping
occurs well before the CNC reach the outflow, the SHF-related
defects appear to be caused indirectly by NCA (Hutson and
Kirby, 2003). This suggests that CNC may modulate signaling
factors in the pharynx.
The first evidence that fibroblast growth factor (FGF)
8 signaling was disrupted in the CNC-deficient pharynx came
from a study examining the primarymyocardial dysfunction also
observed after NCA. We showed in culture that conditioned
media from the NCA pharynx could reproduce the depressed
myocardial Ca2+ transient of the primary heart tube and that the
transient could be rescued with an FGF8b-neutralizing antibody
(Farrell et al., 2001). This suggested that FGF signaling was
elevated after NCA.
FGF8 provides a variety of mitogenic, survival, pro- or anti-
differentiation signals to pattern tissues and is required for nor-
mal craniofacial, cardiac and limb development (Schneider et al.,
2001; Alsan and Schultheiss, 2002; Crossley and Martin, 1995;
Crossley et al., 1996). Although there are at least 4 to
8 alternatively spliced FGF8 isoforms in humans and mouse,
the chick only produces 2 isoforms: fgf8a and fgf8b (Basilico
and Moscatelli, 1992; Haworth et al., 2005). FGF8b isoform has
been shown in the literature to be more biologically potent than
FGF8a isoform. Most of the in vivo embryological studies
comparing the biological activity of the isoforms have been done
by the Nakamura and colleagues working in the chick hindbrain.
They have shown that FGF8b isoform is 100 times more potent
than FGF8a (Sato et al., 2001). The FGF8a and FGF8b isoforms
differ by only 11 amino acids. A recent publication elucidating
the crystal structure of FGF8b, FGF8a and the FGF receptors has
shown that these 11 amino acids greatly enhance the binding
affinity of the FGF8b isoform to the FGF receptors whereas the
FGF8a isoform has very low binding affinity and this accounts
for the potent biological activity of the FGF8b isoform (Olsen et
al., 2006). FGF signaling is mediated via tyrosine kinase
receptors (FGFRs) that act through a number of transduction
pathways. While FGF8-null mice die during gastrulation(Meyers et al., 1998; Sun et al., 1999; Moon and Capecchi,
2000), hypomorphic mice have cardiac outflow, pharyngeal arch
artery and pharyngeal gland defects reminiscent of the NCA
phenotype (Abu-Issa et al., 2002; Frank et al., 2002).
Fgf8 is expressed in the lateral pharyngeal ectoderm and
endoderm at the time CNC begin to populate the caudal pha-
ryngeal arches and as the myocardium is added to the looping
heart from the SHF (Farrell et al., 2001). Because FGF8b
antibody rescued the myocardial calcium transient in culture,
we hypothesized that FGF8 signaling is overabundant in the
pharynx in the absence of the CNC. This excessive signaling
prevents addition of myocardium from the SHF causing a
shortened outflow tract that ultimately results in cardiac arterial
pole alignment defects.
In this study, we demonstrate by quantitative PCR that total
fgf8 and fgf8b message and downstream targets are elevated in
the caudal pharynx in NCA embryos between stages12 and 14,
coinciding with the time the CNC should enter the pharynx.
Using an FGF reporter in transiently transfected cells, we
determined that the FGF8b isoform has much more potent sig-
naling properties than FGF8a. Also using this reporter, we were
able to show that FGF8 signaling was increased in the pharynx
after NCA. All of the indirect effects of NCA, i.e. looping,
addition of myocardium from the SHF, myocardial function and
arterial pole alignment, could be rescued in ovo by treating the
embryos with either anti-FGF8b or the FGFR blocker, SU5402.
This rescue was time and dose-dependent. Conversely, reducing
FGF8 signaling below normal levels in sham-operated embryos
resulted in failure of myocardial addition from the SHF, abnor-
mal looping and arterial pole alignment defects.
Materials and methods
Embryo preparation
NCA and sham-operated embryos were prepared as described previously
(Waldo et al., 1996). At Hamburger and Hamilton stage 10, the vitelline
membrane was torn. FGF8b function blocking antibody (varying concentrations
between 40 and 400 μM, R&D Systems), 10–20 μM of the FGFR1 blocking
compound SU5402 (Calbiochem, La Jolla, CA), PBS (control for FGF8b
antibody) or DMSO/PBS (1:1000 in PBS, SU5402 control) was dropped onto the
embryos. The embryoswere incubated for 24 h (stages 14–16), assessed for heart
looping and collected for either immunohistochemistry or myocardial calcium
transient measurements (see below). Some embryos were incubated until day 9
and examined histologically for arterial pole alignment. In a second series of
experiments, embryos were treated with the anti-FGF8b 24 h after NCA and
assessed for arterial pole alignment at day 9. In all experiments, no differences
were observed between PBS and DMSO/PBS treated control embryos, and
therefore are reported as PBS controls. For cell tracing experiments, SHFs were
injected at stage 14 with Tetramethylrhodamine-succinyl ester (TAMRA-SE,
Molecular Probes) as previously described (Ward et al., 2005) and examined for
migration into the outflow at stage 18.
Quantitative RT-PCR
RNAwas isolated from caudal pharynges of sham or NCA embryos between
stages 12- and 15 using RNAeasy minicolumn (Qiagen) and reverse transcribed
using SuperScript II reverse transcriptase (Invitrogen). A minimum of 11 pools
of RNA was isolated for each stage and condition. Real-time quantitative PCR
analysis was performed with primers specific for hprt, and 18S, fgf8t, fgf8b, as
well as the FGF8 downstream target genes, Pea3, Erm, Er81 and mkp3 using
IcQ Supermix containing SYBR Green (Bio-Rad) with a Bio-Rad quantitative
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were normalized to hprt and 18S standards. Fold change in expression was
determined by setting sham expression levels at one and plotting the relative
expression levels of each gene at each stage in the NCA caudal pharynx.
Significant differences were calculated by unpaired Student's t test with unequal
variance.
Tissue culture and transfections
To find conserved elements within the mkp3 promoter, we compared 100 kb
of DNA sequence upstream of the human, mouse, rat, dog, chicken, frog and
zebrafish mkp3 genes, using the BLAST program. Four conserved regions were
identified spanning about 3000 bp proximal to the 5′UTR that shared over 75%
homology. A 1.9 kb fragment (see Supplementary methods for primer
sequences) was cloned into the GFP expression vector, pEGFPN-1. COS7
cells were used for all the transient transfection experiments. The cells were
cultured in DMEM and 10% fetal bovine serum (Gibco) until 80% confluent.
Next, COS7 cells were transiently transfected with the mkp3-GFP expression
vector using FuGene (Roche) following the manufactures protocols. Transfected
COS7 cells were split to multiwell plates and exposed for 6 h to varying
concentrations of FGF8b, VEGF or EGF proteins, alone or in combination with
the respective antibodies (R&D Systems) in serum-free media in duplicate.
Conditioned media was generated from caudal pharynx explants cultured
overnight in serum-free media. For the caudal pharynx explant co-culture or
conditioned media experiments, transfected cells were cultured overnight alone
or in combination with 100 μM anti-FGF8b (R&D Systems) in serum free
media. To test the difference in FGF8a versus FGF8b signaling, FGF8a or
FGF8b expression vectors (kind gift of Dr. H. Nakamura, Tohoku University,
Japan) were transfected into COS7 cells. Serum-free conditioned media from
these cells were collected and placed on mkp3-GFP transfected COS7 cells with
or without anti-FGF8b in duplicate. All responses were measured by
photographing 5 fields of cells at a set exposure (to avoid counting cells with
very low GFP expression) and counting the number of GFP expressing cells
compared to total number of cells stained with the Hoechst (Molecular Probes)
nuclear marker following the manufacturer's protocol for staining in live cells.
Each measurement represents an average of a minimum of 2 duplicates in at
least 3 separate experiments. Statistical analysis for Mkp3-GFP reporter
experiments was unpaired Student's t test with unequal variance.
Myocardial calcium transient measurement
Heart tubes minus the presumptive atria were dissected from stage 14–16
embryos and loaded with the fluorescent Ca2+ indicators, fura-2 or fluo-4, using
the AM ester forms. Ca2+ transients were recorded in the ventricular region of
spontaneously beating hearts at 100 Hz sampling rate with a microspectro-
fluorometer DeltaScan system from Photon Technology International as
previously described for Ca2+ measurements in explant cultures of cardiac
muscle strips (Farrell et al., 2001). For fluo-4, Ca2+ concentration was calculated
from:
½Ca2þi ¼ KDR=ððKD=½Ca2þrestÞ  Rþ 1Þ
where the KD = 1000 nM (Molecular Probes Handbook), R is the number of
photon counts and [Ca2+]rest is the resting Ca
2+ set at 250 nM (Creazzo et al.,
2004). Measurements were carried out without knowledge of the embryo
treatment.
Immunohistochemistry and cell proliferation
Sham, NCA and NCA embryos treated with or without anti-FGF8b or
SU5402 were collected at stage 15, fixed with Methacarn, embedded in paraffin
and sectioned for immunostaining. HNK-1 (ATCC), visualized with Alexa 488
goat anti-mouse secondary antibody (Molecular Probes) and MF20 (Develop-
mental Studies Hybridoma Bank developed by NICHD and maintained by the
University of Iowa, Department of Biological Sciences) visualized with Alexa
568 goat anti-mouse secondary antibody were carried out as previously
described (Waldo et al., 1996, 1998). BrdU incorporation visualized with
Alexa488 goat anti-mouse secondary antibody was detected as previouslydescribed (Waldo et al., 2005b). The nuclei were stained with Hoechst
(Molecular Probes) following the manufacturer's protocol. The number of
BrdU-positive cells was counted in populations of 50 cells in sagittal sections.
Ten sections for a total of 500 cells were counted per embryo (n = 3 embryos for
each treatment). Statistical analysis used was Student's t test.
Assessment of arterial pole alignment
Hearts from sham-operated and NCA embryos treated with PBS, anti-
FGF8b or SU5402 at stage 10 were harvested at day 9 and arterial pole
alignment was documented. The hearts were fixed overnight in 10% formalin,
paraffin embedded, serially sectioned and stained with hematoxylin and eosin.
The arterial pole was scored as malaligned if the aorta or the aortic portion of the
outflow was not wedged between the tricuspid and mitral valve and shifted to
the right in relation to the pulmonary trunk.
Results
FGF8 signaling is increased after cardiac neural crest ablation
To determine if FGF8 signaling is increased in the caudal
pharynx after NCA, we designed specific primers to total fgf8
(fgf8t), fgf8b and several known downstream targets of FGF8
signaling including the dual phosphatase, mkp3 and the trans-
cription factors, pea3, erm and er81 for quantitative PCR (Fig.
1A). Beginning at stage 12, 24 h after NCA, when CNC are
normally located in the circumpharyngeal ridge, fgf8t and fgf8b
messages were significantly, albeit slightly, increased in the
caudal pharynx from NCA embryos when compared to sham-
operated embryos. At this stage, there was no difference in the
expression levels of FGF8 downstream target genes (Fig. 1A).
Interestingly, the increase in fgf8b expression accounted for the
increase in fgf8t. By stage 13, there was almost a 3-fold increase
in expression of fgf8t and fgf8b in the NCA caudal pharynx.
This accompanied a significant increase in mkp3 expression.
Mkp3 has been previously reported to be one of the earliest
downstream targets to respond to FGF8 signaling (Kawakami et
al., 2003). At stage 14, when the myocardium from the SHF
normally begins to migrate into and lengthen the cardiac
outflow, fgf8b expression was still significantly increased in the
NCA pharynx.Mkp3 remained elevated, and now pea3 and erm
were significantly increased. By stage 15, fgf8t and fgf8b
message levels in the NCA pharynx were not different from
sham, but all of the FGF8 target genes tested were significantly
increased. This suggests that the quantity of FGF8 signaling is
increased in the NCA caudal pharynx at a critical time for the
migration of the myocardium from the SHF into the outflow
tract.
To determine whether the increases in message for fgf8 and
FGF8 downstream targets represent an increase in FGF8
signaling, we designed an expression plasmid that would report
FGF8 signaling. Mkp3 has been used previously as an FGF8
reporter (Kawakami et al., 2003). A reporter construct com-
prising 1.9 kb upstream regulatory sequence of chickmkp3 fused
to GFP was transfected into COS7 cells. The cells were exposed
to increasing concentrations of FGF8b protein. A linear GFP
response was elicited by 1.0–10 ng of FGF8b (Fig. 1B). The
FGF8b activation of mkp3-GFP could be completely inhibited
by the function blocking FGF8b antibody (Fig. 1B) or the
Fig. 1. FGF signaling is increased after NCA. (A) Quantitative PCR analysis of fgf8t, fgf8b, mkp3, erm, pea3 and er81 in caudal pharynx from stages 12–15 NCA
embryos. Expression in NCA pharynx (grey bars) is plotted relative to the sham levels set at one (black line). Stars indicate significance. Bars equal SEM. fgf8t and
fgf8b are increased in NCA pharynx at stage 12 (n = 11, P < 0.05) and stage 13 (n = 11, P < 0.04). At stage 13, mkp3 (P < 0.05) expression in NCA pharynx is
significantly increased compared to sham. At stage 14 (n = 13), expression of fgf8b (P < 0.03) and all but one of the downstream target genes are significantly increased
(pea3 P < 0.02; erm andmkp3 P < 0.05) in the pharynx after NCA. By stage 15 (n = 15), only the downstream targets are significantly elevated (erm and pea3 P < 0.01;
er81 P < 0.04; mkp3 P < 0.02). (B) COS7 cells transiently transfected with mkp3-GFP respond to FGF signaling.Mkp3-GFP is activated by increasing concentrations
of FGF8b (white bar). Maximal response is reached with 10 ng FGF8b. More mkp3-GFP is activated in the cells co-cultured with NCA pharynx (NCA Ph, n = 5)
compared to the sham pharynx (Sh Ph, n = 5, P < 0.008). Anti-FGF8b (aFGF8b) inhibits activation. (C) FGF8b isoform is more active than FGF8a isoform.Mkp3-GFP
reporter cells cultured with increasing volumes of conditioned media from either FGF8a or FGF8b expressing cells. FGF8b conditioned media produce maximal
Mkp3-GFP response (black squares) that is inhibited by anti-FGF8b (open squares). FGF8a (black triangles) or FGF8a plus anti-FGF8b (open triangles) exhibits very
low Mkp3-GFP activity. Error bars equal SD.
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EGF and retinoic acid did not elicit a response from the reporter
(see supplemental data).
To compare the signaling capacity of chick FGF8a versus
FGF8b, we transiently transfected plasmids expressing either
FGF8a or FGF8b into a second set of COS cells. After 24 h, 50–
200 μl of the supernatant from these cells was placed on COS
cells transiently transfected with the mkp3-GFP reporter con-
struct. There was a maximal response of the reporter cells to
increasing amounts of supernatant from the cells expressing
FGF8b (black box line Fig. 1C). The response could be blockedby anti-FGF8b (open box line Fig. 1C). There was no response to
the supernatant from cells expressing FGF8a (black triangle line
in Fig. 1C). These results confirm the results of Sato et al. (2001)
who used in vivo electroporations to show that the effectiveness
of FGF8a is 100-fold less than that of FGF8b in patterning the
mid-hindbrain region.
After establishing the response characteristics of the reporter
construct to FGF8 signaling, we co-cultured COS7 cells tran-
siently transfected with the mkp3-GFP reporter with explants of
dissected caudal pharynx from stage 14 (when most of the
downstream targets are elevated) sham-operated or NCA
Fig. 2. FGF8b antibody (anti-FGF8b) or SU5402 treatment normalizes heart
looping 24 h after NCA. (A) Normal heart loop viewed from the left of stage 15
sham-operated embryo treated with PBS shows the outflow portion of the loop
(white arrowhead) partially obscured by the inflow portion of the loop (black
arrowhead). (B) Abnormal heart loop in PBS-treated NCA embryo shows
outflow portion of the loop (white arrowhead) and the inflow portion (black
arrowhead) are completely visible. (C) Sham-operated embryo after anti-FGF8
treatment has abnormal heart looping. Note the blunted forebrain (fb). (D) Heart
looping appears normal in an NCA embryo after anti-FGF8 treatment. (E) Heart
tube in sham embryo is abnormally looped after SU5402 treatment. (F)
Normally looped heart tube in an SU5402-treated NCA embryo. White arrows
mark the hindbrain defect caused by the NCA in panels B, D, and F. Asterisk
marks flattened hindbrain in shams treated with anti-FGF8 and SU5402. Scale
bar = 0.15 mm.
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more FGF8 signaling in the caudal pharynx from NCA embryos
as compared with the shams. The response to both tissues was
specifically inhibited by anti-FGF8b (Fig. 1B). These data show
that there is elevated FGF8b signaling in the caudal pharynx in
the absence of CNC at a time critical for the migration and
differentiation of the myocardial component of the SHF.
Reducing FGF signaling rescues the early indirect affects of
cardiac neural crest ablation
Because excess FGF8 signaling in the caudal pharynx co-
incided with the time when the myocardial component of the
SHF is added to the outflow tract, we attempted to rescue
looping and addition of myocardium from the SHF by reducing
the level of FGF8 signaling after NCA. Normally in stage 15
embryos, the inflow limb of the heart loop partially obscures the
outflow limb when viewed from the left (Fig. 2A). After NCA,
the outflow limb is displaced ventrally and cranially, so that both
the outflow and inflow limbs are visible when viewed from the
left (Fig. 2B). This abnormal looping is due to a failure of the
SHF to add myocardium that normally lengthens the outflow
portion of the heart tube (Yelbuz et al., 2002; Waldo et al.,
2005b), and is one of the first defects observed after NCA. We
examined looping in the NCA embryos treated with FGF8
antibody or SU5402 to determine if heart looping could be
rescued. Looping was normal in 67% and 50% of the NCA
embryos treated with antibody or SU5402 as compared to only
23% of untreated NCA embryos (Table 1, Figs. 2D, F and G).
Interestingly, looping was abnormal in sham-operated embryos
treated with either the FGF8b antibody or SU5402 (Figs. 2C and
E). Only 33% (SU5402) and 53% (anti-FGF8b) showed normal
looping (Table 1). This suggests that normal cardiac looping is
sensitive to FGF8 signaling. Evidence that FGF8 signaling was
specifically inhibited in these embryos is corroborated by ab-
normal forebrain and frontonasal development in the shams
treated with FGF8 inhibitors (Figs. 2C and E). The frontonasal
region has been shown to require FGF8 signaling for normal
development.
Previously, we have shown that cells migrating from the SHF
express HNK-1 as they move into the outflow tract and dif-
ferentiate into myocardium (Waldo et al., 2001, 2005a). After
NCA, HNK-1 expression is significantly reduced during the
myocardial migratory phase in the SHF, indicating that the
myocardial cells derived from the SHF are not incorporated into
the outflow myocardium after NCA (Figs. 3A and B) (Yelbuz
et al., 2002; Waldo et al., 2005b). We examined HNK-1 ex-
pression in NCA embryos 24 h after treatment with either anti-
FGF8b or SU5402 to see if the myocardial migration from
the SHF migration could be rescued. Both SU5402 and the
FGF8b antibody rescued HNK-1 expression in the SHF (arrows
in Figs. 3C and D).
To directly show that the migration of the SHF cells was
rescued in the NCA embryos treated with anti-FGF8b, we
labeled the SHF with DiI and caged rhodamine, and examined
the embryos 24 h later for labeled cells in the outflow myo-
cardium. Labeled myocardial cells were found in the outflowtract of sham embryos treated with PBS and in the neural crest-
ablated embryos treated with anti-FGF8b (Figs. 3E and H),
while as previously described, none were found in the NCA
embryo (Waldo et al., 2005b and Fig. 3F). The embryos were
sectioned to confirm that the labelingwas in themyocardial layer
(data not shown). Rescue of the myocardial component by
reducing FGF8 signaling in NCA embryos suggests that the SHF
is exposed to too much FGF8 signaling when CNC are not
present in the caudal pharynx. Interestingly, the sham-operated
embryos treated with anti-FGF8b had no labeled myocardial
cells in the outflow (Fig. 3G). Therefore, the abnormally looped
and shortened outflow tract observed in sham-operated embryos
in which FGF8 signaling is reduced to below normal levels is
Table 1
Summary of heart looping phenotype in all treatment groups
Treatment % normal heart looping
Sham + PBS (n = 11) 90
NCA + PBS (n = 13) 23
NCA + anti-FGF8 (n = 18) 67
NCA + SU 5402 (n = 8) 50
Sham + anti-FGF8 (n = 15) 53
Sham + SU 5402 (n = 6) 33
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to migrate into the heart tube. Hence, the migration of SHF-
derived myocardium is particularly sensitive to FGF8 levels.Recently, we have shown that there is an increase in proli-
feration in the SHF in NCA embryos (Waldo et al., 2005b). If
FGF8 oversignaling is causing increased proliferation, wewould
predict that treatment with FGF8b antibody would reduce pro-
liferation to normal levels. We examined BrdU incorporation in
sham and NCA stage 15 embryos with or without anti-FGF8b
treatment. Sham embryos treated with PBS had an average of
26% BrdU-positive cells as compared with 46% after NCA (P <
0.0001, Fig. 3I and Supplementary Fig. 2). Proliferation was
decreased to 31% BrdU-positive cells in NCA embryos treated
with anti-FGF8b, which was not significantly different from
the number of proliferating cells in sham embryos (P = 0.15),
but was significantly lower when compared to the untreated
NCA group (P = 0.01, Fig. 3I, and Supplementary Fig. 2). This
indicates that the anti-FGF8b treatment normalizes prolifera-
tion in the SHF of NCA embryos. Interestingly, proliferation in
sham-operated embryos treated with anti-FGF8b was signi-
ficantly lower: 15% of the cells were BrdU positive, a dramatic
reduction when compared to the sham or neural crest-ablated
embryos not treated with anti-FGF8b or NCA embryos treated
with anti-FGF8b (P < 0.0001). These data suggest that
proliferation and migration of the myocardial component of
the SHF are linked to precisely controlled levels of FGF8
signaling.
Previously we have shown that the myocardial calcium tran-
sient is depressed more than 30% in stage 14 chick embryos after
NCA (Waldo et al., 1999). To test if the Ca2+ transient could be
rescued, we treated NCA embryos in ovo with either FGF8b
antibody or SU5402 within 4 h after the ablation (stages 9–10).
At stage 14, the presumptive ventricular regions of the heart
tubes were excised for myocardial Ca2+ transient measurements.
Fig. 4 shows that the magnitude of the myocardial Ca2+ transient
was reduced after NCA when compared to the sham-operated
control. Treatment with either FGF8b antibody or SU5402 re-
stored the myocardial Ca2+ transient to its normal level in NCA
embryos. With either treatment, the magnitudes of the transients
were generally larger than those in the sham controls (Figs. 4A–
C). There were no apparent differences in the diastolic Ca2+
level, consistent with previous observations (Creazzo et al.,
1997; Farrell et al., 2001).Fig. 3. FGF8 antibody or SU5402 rescues migration and proliferation of the
SHF in neural crest-ablated embryos. Sagittal sections through the outflow and
SHF (white arrow A–D) of a stage 16 chick, stained for HNK-1 (green,
migrating SHF) and MF-20 (red, myocardium). (A) The SHF expresses HNK-
1 as it migrates into the caudal outflow. (B) The SHF in the NCA embryo
expresses very little HNK-1. HNK-1 expression is restored to normal in an
NCA embryo 24 h after treatment with anti-FGF8 (C) or SU5402 (D). (E–H)
Stage 18 chick embryos 24 h after labeling SHF with DiI and caged
rhodamine. SHF cells migrate into the outflow (white arrows) in the sham (E)
and the NCA treated with anti-FGF8 (H). No labeled myocardial cells are
found in the NCA (F) or sham-operated embryos treated with anti-FGF8 (G).
(I) Graph showing average number of BrdU positive cells per 100 cells
counted in the SHF. The SHF of NCA embryos showed a significant increase
in the number of BrdU-positive cells (star) as compared to shams. Proliferation
in SHF from NCA treated with anti-FGF8b was not significantly different
from sham (P = 0.15). Proliferation in shams treated with aFGF8 is signi-
ficantly lower than PBS treated shams (P = 0.0007). Error bars represent SD.
Scale bar = 50 um for A–D.
Fig. 4. Anti-FGF8b or SU5402 treatment rescues Ca2+ transients after NCA. (A) An example of Ca2+ transients in the ventricular region of stage 14 hearts in sham-
operated controls, after NCA alone or NCAwith treatment of the embryo with SU5402. The Ca2+ transient that is reduced after NCA is restored to normal when treated
with SU5402. (B and C) Average percent increase in the magnitude of the Ca2+ transient in anti-FGF8 (B) or SU5402 (C) treatments. Both treatments restored the Ca2+
transient to normal after NCA. Single factor ANOVA indicated significance at P = 0.02 and P = 0.003 for anti-FGF8 antibody and SU5402 treatment, respectively.
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effects of NCA, i.e. abnormal looping, addition of myocardium
from the SHF to the outflow tract, proliferation of cells in the
SHF and myocardial calcium transient, are rescued by treatment
of the embryos with FGF8 blocking agents.
Inhibition of FGF8 signaling rescues arterial pole alignment in
NCA embryos
The final position of the arterial pole is attained during the
later stages of outflow septation when the aortic side of the
outflow tract nestles or “wedges” between the atrioventricular
valves (Figs. 5A–AW). In chick, outflow septation and alignment
are complete by embryonic day 8. Malalignment of the arterial
pole occurs when the aortic side of the outflow fails to wedge
between the atrioventricular valves and stays in a “side-by-side”
orientation with the pulmonary artery. In NCA embryos, not
only does the aorticopulmonary septum fail to form, but the
common outflow vessel is shifted to the right to arise from the
right ventricle (Figs. 5B–BW). Even though separate aortic and
pulmonary arterial trunks do not form, the aortic and pulmonary
sides of the common arterial trunk can be identified by the
positions of the coronary artery ostia. Thus, Fig. 5BW shows the
side-by-side relationship of the aortic and pulmonary compo-
nents of the common trunk (compare with Fig. 5AW).
Because the early defects could be rescued by reducing FGF
signaling, we wondered if the final outflow alignment could
also be rescued. NCA embryos were treated with anti-FGF8b or
SU5402 at stage 9–10 and re-incubated until embryonic day 9
when the hearts were analyzed for outflow alignment. All heartsfrom untreated NCA embryos had PTA (Table 2). The majority
of these common trunks (88%) failed to wedge with respect to
the inflow valves and were shifted to the right (compare Figs.
5AW with Fig. 5BW). Because the CNC that make the aorti-
copulmonary septum are missing, the anti-FGF8b or SU5402
treatment was not expected to rescue the PTA. However, wedg-
ing of the aortic side of the common outflow was rescued in 78%
and 100%, respectively, of the NCA embryos treated with anti-
FGF8 (n = 7, Figs. 5C–CW) or SU5402 (n = 6, Figs. 5D–DW). In
addition, the ventricular septal defect in all of the rescued hearts
was smaller and closer to the outflow valves, when compared to
the untreated NCA hearts (arrowhead in Figs. 5B, C′ and D′).
Decreasing FGF8 signaling in sham embryos causes arterial
pole defects
Because decreasing FGF8 signaling in sham-operated em-
bryos caused abnormal development of the SHF, we examined
hearts from shams treated with either anti-FGF8 or SU5402 to
determine if the aorta and pulmonary trunk were malaligned. An
overriding aorta in a side-by-side orientation with the
pulmonary trunk occurred in 42% and 54%, respectively of
anti-FGF8b- or SU5402-treated embryos (Table 2, Figs. 6C–D).
Pulmonary stenosis or atresia, a hallmark of tetralogy of Fallot,
was observed in 2 hearts (Figs. 6E–F). Normally by this stage
in heart development, the left 4th arch artery has disappeared
(Fig. 6A) but in the heart shown in Fig. 6E there was a
persisting left 4th arch artery. The most severe defect was seen
in one heart with transposition of the great arteries (Figs. 6G–H)
with a common atrioventricular canal (data not shown). The left
Fig. 5. FGF8 antibody or SU5402 treatment restores wedging of the aortic side of the outflow in day 9 hearts of NCA embryos. Hematoxylin and eosin stained
transverse sections of hearts beginning at the level of the inflow valves and progressing distally to the level of the outflow valves. (A–AW) Sham-operated embryo
treated with PBS shows that the aortic outlet (Ao) is wedged between the tricuspid (T) and mitral (M) valves. The aortic outlet stays in this position in the more distal
sections at the level of the semilunar valves (A′ and AW). (B–BW) PBS-treated NCA embryo has a ventricular septal defect (black arrowhead in panel B) at the level of
the tricuspid and mitral valves with the aortic outlet shifted to the right. The aortic portion of the PTA is not wedged and stays to the right of the pulmonary portion of
the outflow even at the level of the semilunar valves (BW) indicating the aortic side of the outflow is malaligned over the right ventricle (compare AWwith BW). Anti-
FGF8-treated NCA (C–CW) and SU5402-treated NCA (D–DW) embryos have a ventricular septal defect (black arrowhead panels C′ and D′) in a more distal position
compared to the NCA plus PBS (compare with panel B). With either treatment, the aortic outlet is wedged between the tricuspid and mitral valves and remains wedged
behind the pulmonary portion of the common outflow (CWand DW) indicating a rescue of arterial pole alignment even though PTA still occurs (compare panels AW, BW,
CW and DW). Scale bar = 100 μm.
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but divided into the right and left ductus arteriosus indicating that
it was the pulmonary trunk rather than the aorta. The right
ventricular outlet was in the normal position but ultimately
divided into the systemic arteries including the persisting left 4th
arch artery (Figs. 6H–H′). Therefore, the aorta originated entirely
from the right ventricle and the pulmonary trunk originated from
the left ventricle. These results suggest that addition of the myo-
cardial cells from the SHF to the outflow tract is critical for normal
looping which is necessary for normal arterial pole alignment.
Time and amount of reduction in FGF8 signaling are
important for alignment
The rescue of arterial pole alignment was dose- and time-
dependent. None of the hearts from NCA embryos treated withTable 2
Summary of arterial pole alignment defects at day 9
Treatment Concentration Wedged PTA
NCA + PBS 1× 2 (12%) 16
NCA + anti-FGF 40 μM–100 μM 7 (78%) 9
NCA + anti-FGF >100 μM 0 7
NCA + SU 5402 20 μM 6 (100%) 5
Sham + PBS 1× 12 (100%) 0
Sham + anti-FGF 40 μM 3 (75%) 0
Sham + anti-FGF 100 μM 15 (58%) 0
Sham + SU 5402 20 μM 6 (46%) 0
Abbreviations: PTA, persistent truncus arteriosus; Ov Ao, overriding aorta; Pul stengreater than 100 μM of the anti-FGF8 had wedging of the aortic
side of the common trunk (data not shown, Table 2, n = 7).
These data taken together with the arterial pole malalignments
in the sham-treated group suggest that too much or too little
FGF8 signaling is detrimental for arterial pole development and
viability.
Interestingly, when the sham-operated embryos were treated
with a lower dose of FGF8 antibody (40 μM), arterial pole
alignment and septationwere normal but the neural crest-derived
smooth muscle tunics of the great arteries were much thicker
than normal (4 out of 4 embryos, Figs. 6I and J). The walls were
so overgrown that the lumens of the vessels were almost com-
pletely occluded. This thickening was not observed with the
higher doses of anti-FGF8 antibody. These results suggest that
the arterial pole and the arch arteries require different levels of
FGF signaling for normal development.Ov Ao Pul Sten Ao Ar Sten Total
14 (88%) 16
2 (22%) 1 9
7 (100%) 7
0 6
0 12
1 (25%) 4 4
11 (42%) 1 26
7 (54%) 1 13
, pulmonary stenosis; Ao Ar Sten, aortic arch artery stenosis.
Fig. 6. Reducing normal levels of FGF signaling causes arterial pole alignment defects. (A, C, E and G) Ventral view of whole hearts and line drawings shows the
position of outflow vessels and arch artery derivatives in day 9 hearts. (B, D and F) Atria have been dissected away to show a 4-valve view. (A) Sham PBS-treated heart
has normal wedging and alignment of the aorta (Ao) behind the pulmonary (P) and between the mitral and tricuspid valves (M and T in B). (C and D) Anti-FGF8-
treated sham with DORV has the characteristic side-by-side position of the aorta and pulmonary trunk. (E and F). Pulmonary atresia in SU5402-treated sham with the
aorta displaced to the right comparable to Tetralogy of Fallot (TOF). (G, H and H′) Anti-FGF8-treated sham shows the aorta ventral to the pulmonary trunk, similar to
transposition of the great arteries (TGA). (H and H′) Sections indicate transposed aorta and pulmonary trunk. The pulmonary, dividing into right and left ductus
arteriosus (RD and LD), arises from the left ventricular outlet while the aorta, dividing into the right and left brachiocephalics (RB and LB), arises from the right
ventricular outlet. (I and J) The smooth muscle wall (arrows) of the aortic arch arteries in a sham embryo treated with 40 μM of anti-FGF8 (J) is thickened compared to
the sham (I). (L) Truncated lower limb of NCA embryo treated with anti-FGF8 at stage 14 (compare to PBS-treated K). L4, left 4th arch artery (Black scale
bar = 100 μm; white scale bar = 1 mm).
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not the treatment affected arterial pole alignment. When NCA
embryos were treated with anti-FGF8 or SU5402 at stage 14, a
time when the SHF has already begun to lengthen the outflow,
alignment of the arterial pole was not rescued. None of the
hearts showed wedging of the aortic side of the common trunk
(n = 5, data not shown). In addition, none of the sham-operated
embryos treated at stage 14 with antibody had arterial pole
malalignment defects. However, the efficacy of the antibody
could be seen in limb truncations that occurred in both sham and
NCA groups (Figs. 6K and L). No limb defects were observed
in the embryos treated at earlier times. The limb defects were
expected as FGF8 signaling has been shown by many groups tobe required for limb outgrowth (Mahmood et al., 1995; Martin,
2001). The lack of limb defects in the earlier treatment group
suggests that FGF8 antibody and SU5402 inhibit FGF signaling
for a limited time.
Discussion
This study shows that the SHF is particularly sensitive to
FGF8 because too much or too little FGF8 signaling results in
abnormal development of the myocardial component of the
SHF that leads to arterial pole alignment defects. Abnormal
development of the myocardial component of the SHF is
manifest as too much or too little proliferation of the myocardial
495M.R. Hutson et al. / Developmental Biology 295 (2006) 486–497precursor cells in the SHF, which appears to be incompatible
with normal migration and differentiation. Finally, we show that
pulmonary stenosis is the result of defective development of the
SHF and not defective outflow septation.
The SHF adds myocardium and later smooth muscle to the
outflow end of the heart tube to form the myocardial-to-
smooth muscle junction of the arterial pole at the level of the
semilunar valves. In previous studies, we have shown that
NCA results in abnormal heart tube looping, failure of the
myocardial component of the SHF to migrate, decreased
myocardial volume and increased in proliferation of the SHF
cells. These are all defects indirectly caused by NCA (Yelbuz
et al., 2002, 2003; Waldo et al., 2005b) because the defects are
initiated a full 2 days before the CNC arrive in the distal
outflow tract and because the CNC are not in physical
proximity of the SHF at the time when abnormal development
is first seen. The findings led us to the hypothesis that FGF8
signaling in the caudal pharynx is misregulated in the absence
of cardiac neural crest.
The importance of FGF8 signaling in arterial pole develop-
ment is supported by studies in mouse and human. In humans,
DiGeorge and velocardiofacial syndromes are associated with
the deletion of chromosome 22q11.2. TBX1, a T-box containing
transcription factor expressed in the SHF, has been identified
in mouse genetic models of 22q11.2 deletion (Jerome and
Papaioannou, 2001; Lindsay et al., 1999, 2001; Merscher et al.,
2001) and studies in human patients (Yagi et al., 2003), as having
a major role in the arterial pole related defects. TBX1 has been
shown to be required for outflow lengthening and final align-
ment in mice. Xu et al. (2004) used a tissue-specific knockout of
Tbx1 in SHF to show that TBX1 is required for normal pro-
liferation in the SHF. Reduced proliferation in the SHF led to
contribution of fewer myocardial cells to the outflow myocar-
dium from the SHF and resulted in arterial pole alignment
defects similar to the ones reported for NCA.
Importantly, several studies have also suggested that TBX1
regulates the expression of Fgf8 (Abu-Issa et al., 2002; Frank
et al., 2002; Kochilas et al., 2002; Vitelli et al., 2002) and it is
well established that Fgf8 hypomorphic mice have similar
arterial pole alignment defects to those seen after NCA (Abu-
Issa et al., 2002; Frank et al., 2002). Inactivation of Fgf8 in
Tbx1-expressing cells results in a DiGeorge phenotype (Brown
et al., 2004). Our data add to the growing body of evidence
that proliferation in the SHF must be tightly regulated for the
SHF to contribute myocardium to the outflow tract, and this
contribution is required for normal arterial pole alignment.
Even though FGF8 has been shown to be a mitogen, further
studies will be necessary to determine if increased in
proliferation in the SHF is a direct consequence of increased
FGF8 signaling. In humans, when the aorta is positioned to the
right of the pulmonary trunk, i.e. “dextroposed”, the defect is
classified as overriding aorta. If the aorta overrides more than
50% it is classified as DORV. If the pulmonary trunk is smaller
and the aorta is overriding, the defect is classified as tetralogy
of Fallot. We have previously reported that malalignment
defects are produced by NCA. However, this study and a
recent one in which the right SHF was ablated (Ward et al.,2005), both show pulmonary stenosis and atresia. These two
defects have never been seen after NCA which is limited to
overriding aorta or DORV. Therefore, pulmonary stenosis or
atresia as seen in tetralogy of Fallot is more likely due to
abnormal addition of cells from the SHF and not to NCA. The
pulmonary stenosis/atresia phenotype appears to be directly
related to poor proliferation of the SHF and not excessive
proliferation as is seen after NCA when Fgf8 signaling is also
excessive.
This study and several earlier reports from our lab have
shown that the myocardial calcium transient is reduced after
NCA, and it was shown that anti-FGF8b can rescue the calcium
transient in culture (Farrell et al., 2001). We now show that the
calcium transient is also rescued in NCA embryos by reducing
FGF8 signaling. We still do not fully understand the mechanism
by which the myocardial function is depressed after NCA. Other
studies have shown that FGF2 can repress the expression of the
ryanodine receptor that mediates calcium release from the sar-
coplasmic reticulum (Marks et al., 1991). FGF2 has also been
shown to depress the myocardial calcium transient in cultured
adult rat cardiomyocytes (Ishibashi et al., 1997). A recent study
shows that periodic calcium activity, i.e. transients, elicited by
FGF through activation of phospholipase C correlates tempo-
rally with the onset of gene expression in Xenopus embryos
which suggests that there might be a causal relationship between
calcium transients and gene expression (Diaz et al., 2005). Other
FGFs are expressed in the myocardium and it is possible that
levels of FGF8 signaling in the caudal pharynx affect myocardial
FGF production.
The importance of CNC in arterial pole development takes
two forms: direct and indirect. CNC form the outflow
septation complex that is required for division of the outflow
tract into systemic and pulmonary circulations (Kirby et al.,
1983; Waldo et al., 1998). In addition, our study now shows
that CNC modulate FGF8 signaling in the caudal pharynx
during the temporal window when myocardial cells are added
to the outflow tract from the SHF. Because the level of FGF8
signaling is critical for addition of these cells to the outflow
tract, we believe that the role of CNC in modulating growth
factor availability in the pharyngeal apparatus may impact
widely on pharyngeal development in addition to the outflow
tract. The next step is to identify the mechanism(s) that CNC
use to affect this modulation and whether this signaling
directly or indirectly affects the SHF. Studies are underway
examining the potential role of natural FGF signaling
antagonists, such as the Sprouty family of genes and Mkp3,
generally expressed in tissues targeted by FGF ligands are to
be examined in the SHF and pharynx. Sprouty1 and Sprouty2
are expressed in dissected SHF containing ventral pharynx of
mouse and chick (unpublished data). Our quantitative PCR
experiments show that many of the downstream targets of
FGF signaling are normally present in the caudal pharynx and
are elevated after neural crest ablation including the MKP3
which has been shown to be a negative regulator of FGF8
signaling (Kawakami et al., 2003). In the limb, Mkp3
expressed in the mesenchyme plays a key role in mediating
the proliferative, anti-apoptotic signaling produced by apical
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Further studies are needed to determine the role of these
FGF8 signaling antagonist in the addition of the SHF with too
much or too little FGF signaling.
Our data add to the growing body of evidence that the proper
addition of the myocardium from the SHF to the looping heart
tube is necessary for final arterial pole alignment, and that
different regions and cell types in the caudal pharynx require
different levels of FGF8 signaling. For example, in the Fgf8
hypomorphic mice, there is an increase in cell death in the neural
crest, suggesting that CNC require high levels of FGF8 for
normal development (Abu-Issa et al., 2002; Frank et al., 2002).
However, we saw no direct effects of reducing FGF on cardiac
neural crest cells in the pharynx or outflow tract when treated at
early stages, this may reflect a transient reduction of FGF
signaling rather than a continuous reduction of FGF8 as in the
hypomorphic mice. The only defect in neural crest-derived
structures we did observe was a thickening of the tunica media of
the arch arteries.
In addition to levels of FGF8, the source of the FGF8 signal
may also be important. In mouse and chick, the FGF8 has been
shown to be critical for early stages of cardiac mesoderm
formation. In the mouse, FGF8 is expressed in the cardiogenic
mesoderm (E7.75–E8.0) as well as the underlying inducing
endoderm whereas in the chick it is only expressed in the
underlying endoderm (Crossley and Martin, 1995; Alsan and
Schultheiss, 2002). This endodermal FGF8 expression in the
chick has been shown to be important in combination with
BMPs in inducing cardiogenic mesoderm. In the mouse, the
FGF8 expression disappears in the cardiac tissue and is
expressed in the lateral pharyngeal ectoderm and endoderm,
although some investigators report low levels FGF8 expression
in the SHF, outflow tract and primitive right ventricle in an
FGF8lacZ reporter line (Erik Meyers personal communica-
tion). The stage which we applied the FGF8 antibody would
not affect the earliest cardiogenic mesoderm but certainly
would affect the cardiogenic mesoderm in the SHF. At these
stages, the critical source of FGF8, lateral pharyngeal ectoderm
and endoderm, is the same in the mouse and chick. Some
studies in the mouse have begun to address which the source of
FGF8 is critical for which developmetal processes. In the
mouse, tissue-specific ablation of Fgf8 in the pharyngeal arch
ectoderm results in arch artery patterning defects but no arterial
pole defects (Macatee et al., 2003). The same study also
reported a tissue-specific ablation of FGF8 in the endoderm
and ectoderm and these mice had low incidence of aortic valve
and coronary artery patterning defects (Macatee et al., 2003).
However, the timing of this knockout is later than the
ectodermal knockout and may only affect the smooth muscle
component of the SHF. A third tissue-specific knockout of
FGF8 using a Tbx1Cre ablated FGF8 from the early
cardiogenic mesoderm and endoderm (but not the ectoderm)
caused outflow defects (Brown et al., 2004). This suggests that
the FGF8 produced by the pharyngeal endoderm may be more
important for normal outflow development but final judgment
about the specificity and timing of different sources of FGF8
signaling must be tested in other ways.Acknowledgments
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